Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Amoxapine is a tricyclic antidepressant (TCA) derivative structurally related to loxapine, primarily utilized in the treatment of major depressive disorder. With the chemical formula C18H19ClN2O2 and a molecular weight of approximately 334.81 g/mol, this compound features a dibenzoxazepine core substituted with a chloro group and an amide side chain. Its unique CAS registry number is 304-69-6, which serves as its universal identifier in chemical databases and pharmaceutical literature.
The primary mechanism of action involves the inhibition of serotonin and norepinephrine reuptake at presynaptic neuronal membranes, thereby increasing the concentration of these neurotransmitters in the synaptic cleft. Unlike some other TCAs, Amoxapine possesses a more rapid onset of therapeutic effect for certain patients and exhibits mild antipsychotic properties due to its metabolite, 7-hydroxyamoxapine, which acts as a dopamine D2 receptor antagonist. This dual activity makes it particularly effective for depression accompanied by anxiety or psychotic features, although its use has declined in recent years due to safety concerns.
Clinically, Amoxapine is indicated for the management of moderate to severe depressive episodes. It helps alleviate symptoms such as persistent sadness, loss of interest, fatigue, and sleep disturbances. However, its application requires careful monitoring because of potential side effects including sedation, dry mouth, constipation, urinary retention, and orthostatic hypotension. A significant risk associated with high doses or overdose is the development of seizures, necessitating strict adherence to prescribed dosages. Additionally, patients must be monitored for signs of agranulocytosis, though this is rare.
Despite the availability of newer antidepressants like SSRIs, Amoxapine remains a valuable option in specific clinical scenarios where traditional treatments have failed or when a patient presents with comorbid psychotic symptoms. Its pharmacokinetic profile includes good oral bioavailability and extensive hepatic metabolism via cytochrome P450 enzymes. Physicians typically initiate therapy at low doses, gradually titrating up to achieve therapeutic levels while minimizing adverse reactions. Overall, Amoxapine represents a potent pharmacological tool in psychiatry, balancing efficacy with a distinct safety profile that demands professional oversight during long-term treatment regimens.